Cardioprotective Potential of N-acetyl Cysteine Against Hyperglycaemia-induced Oxidative Damage: a Protocol for a Systematic Review

Overview

Journal Syst Rev

Publisher Biomed Central

Date 2017 May 14

PMID 28499416

Citations 10

Authors

Phiwayinkosi V Dludla

Bongani B Nkambule

Stephanie C Dias

Rabia Johnson

Affiliations

Soon will be listed here.

Abstract

Background: Hyperglycaemia-induced oxidative damage is a well-established factor implicated in the development of diabetic cardiomyopathy (DCM) in diabetic individuals. Some of the well-known characteristics of DCM include increased myocardial left ventricular wall thickness and remodelling that result in reduced cardiac efficiency. To prevent this, an increasing number of pharmacological compounds such as N-acetyl cysteine (NAC) are explored for their antioxidant properties. A few studies have shown that NAC can ameliorate hyperglycaemia-induced oxidative damage within the heart. Hence, the objective of this review is to synthesise the available evidence pertaining to the cardioprotective role of NAC against hyperglycaemia-induced oxidative damage and thus prevent DCM.

Methods: This systematic review protocol will be reported in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. We will perform a comprehensive search on major databases such as EMBASE, Cochrane Library, PubMed and Google scholar for original research articles published from January 1960 to March 2017. We will only report on literature that is available in English. Two authors will independently screen for eligible studies using pre-defined criteria, and data extraction will be done in duplicate. All discrepancies will be resolved by consensus or consultation of a third reviewer. The quality of studies will be checked using Cochrane Risk of Bias Assessment Tool and The Joanna Briggs Institute (JBI) Critical Appraisal tools for non-randomised experimental studies. Heterogeneity across studies will be assessed using the Cochrane Q statistic and the inconsistency index (I ). We will use the random effects model to calculate a pooled estimate.

Discussion: Although several studies have shown that NAC can ameliorate hyperglycaemia-induced oxidative damage within the heart, this systematic review will be the first pre-registered synthesis of data to identify the cardioprotective potential of NAC against hyperglycaemia-induced oxidative damage. This result will help guide future research evaluating the cardioprotective role of NAC against DCM and better identify possible mechanisms of action for NAC to prevent oxidative damage with a diabetic heart.

Systemic Review Registration: PROSPERO CRD42017055851 .

Citing Articles

A Comprehensive Review on the Significance of Cysteine in Various Metabolic Disorders; Particularly CVD, Diabetes, Renal Dysfunction, and Ischemic Stroke.

Aziz N, Wal P, Sinha R, Shirode P, Chakraborthy G, Sharma M Curr Protein Pept Sci. 2024; 25(9):682-707.

PMID: 38766817 DOI: 10.2174/0113892037287215240424090908.

Anti-inflammatory and anti-apoptotic effects of N-acetylcysteine in diabetic rat corneal epithelium.

Hwang S, Park J, Park J, Kang S, Chung H, Lee H Int J Ophthalmol. 2021; 14(12):1805-1812.

PMID: 34926192 PMC: 8640769. DOI: 10.18240/ijo.2021.12.01.

Drug-Induced Liver Injury: Clinical Evidence of N-Acetyl Cysteine Protective Effects.

Ntamo Y, Ziqubu K, Chellan N, Nkambule B, Nyambuya T, Mazibuko-Mbeje S Oxid Med Cell Longev. 2021; 2021:3320325.

PMID: 34912495 PMC: 8668310. DOI: 10.1155/2021/3320325.

Relationship between oxidative stress and nuclear factor-erythroid-2-related factor 2 signaling in diabetic cardiomyopathy (Review).

Wu X, Huang L, Liu J Exp Ther Med. 2021; 22(1):678.

PMID: 33986843 PMC: 8111863. DOI: 10.3892/etm.2021.10110.

N-Acetyl Cysteine Targets Hepatic Lipid Accumulation to Curb Oxidative Stress and Inflammation in NAFLD: A Comprehensive Analysis of the Literature.

Dludla P, Nkambule B, Mazibuko-Mbeje S, Nyambuya T, Marcheggiani F, Cirilli I Antioxidants (Basel). 2020; 9(12).

PMID: 33339155 PMC: 7765616. DOI: 10.3390/antiox9121283.

References

Giam B, Chu P, Kuruppu S, Smith A, Horlock D, Kiriazis H . N-acetylcysteine attenuates the development of cardiac fibrosis and remodeling in a mouse model of heart failure. Physiol Rep. 2016; 4(7). PMC: 4831326. DOI: 10.14814/phy2.12757. View

Burgunder J, Varriale A, Lauterburg B . Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol. 1989; 36(2):127-31. DOI: 10.1007/BF00609183. View

Dludla P, Muller C, Joubert E, Louw J, Essop M, Gabuza K . Aspalathin Protects the Heart against Hyperglycemia-Induced Oxidative Damage by Up-Regulating Nrf2 Expression. Molecules. 2017; 22(1). PMC: 6155802. DOI: 10.3390/molecules22010129. View

Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M . Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2014; 38(1):140-9. DOI: 10.2337/dc14-2441. View

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-6. PMC: 2335261. DOI: 10.1136/bmj.39489.470347.AD. View

Fischell T . Contrast loaded with N-acetylcysteine for coronary imaging during percutaneous coronary intervention: a new concept for renal and myocardial protection during percutaneous coronary intervention. JACC Cardiovasc Interv. 2009; 2(3):222-3. DOI: 10.1016/j.jcin.2008.12.007. View

Boudina S, Abel E . Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord. 2010; 11(1):31-9. PMC: 2914514. DOI: 10.1007/s11154-010-9131-7. View

Meyer M, LeWinter M, Bell S, Chen Z, Selby D, Singla D . N-acetylcysteine-enhanced contrast provides cardiorenal protection. JACC Cardiovasc Interv. 2009; 2(3):215-21. PMC: 2819370. DOI: 10.1016/j.jcin.2008.11.011. View

10.

SUDDARTH S . Acetylcysteine, a new and effective mucolytic agent. Bull Geisinger. 1963; 15:65-9. View

11.

Eurich D, Majumdar S, McAlister F, Tsuyuki R, Johnson J . Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005; 28(10):2345-51. DOI: 10.2337/diacare.28.10.2345. View

12.

Haffner S, Lehto S, Ronnemaa T, Pyorala K, Laakso M . Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339(4):229-34. DOI: 10.1056/NEJM199807233390404. View

13.

Haleagrahara N, Julian V, Chakravarthi S . N-acetylcysteine offers cardioprotection by decreasing cardiac lipid hydroperoxides and 8-isoprostane level in isoproterenol-induced cardiotoxicity in rats. Cardiovasc Toxicol. 2011; 11(4):373-81. DOI: 10.1007/s12012-011-9132-0. View

14.

Wu X, Luo A, Zhou Y, Ren J . N-acetylcysteine reduces oxidative stress, nuclear factor‑κB activity and cardiomyocyte apoptosis in heart failure. Mol Med Rep. 2014; 10(2):615-24. PMC: 4094772. DOI: 10.3892/mmr.2014.2292. View

15.

Johnson R, Dludla P, Joubert E, February F, Mazibuko S, Ghoor S . Aspalathin, a dihydrochalcone C-glucoside, protects H9c2 cardiomyocytes against high glucose induced shifts in substrate preference and apoptosis. Mol Nutr Food Res. 2016; 60(4):922-34. DOI: 10.1002/mnfr.201500656. View

16.

Dludla P, Muller C, Louw J, Joubert E, Salie R, Opoku A . The cardioprotective effect of an aqueous extract of fermented rooibos (Aspalathus linearis) on cultured cardiomyocytes derived from diabetic rats. Phytomedicine. 2013; 21(5):595-601. DOI: 10.1016/j.phymed.2013.10.029. View

17.

Pappachan J, Varughese G, Sriraman R, Arunagirinathan G . Diabetic cardiomyopathy: Pathophysiology, diagnostic evaluation and management. World J Diabetes. 2013; 4(5):177-89. PMC: 3797883. DOI: 10.4239/wjd.v4.i5.177. View

18.

Tarquini R, Lazzeri C, Pala L, Rotella C, Gensini G . The diabetic cardiomyopathy. Acta Diabetol. 2010; 48(3):173-81. DOI: 10.1007/s00592-010-0180-x. View

19.

Chaumais M, Ranchoux B, Montani D, Dorfmuller P, Tu L, Lecerf F . N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. Respir Res. 2014; 15:65. PMC: 4065537. DOI: 10.1186/1465-9921-15-65. View

20.

Giacco F, Brownlee M . Oxidative stress and diabetic complications. Circ Res. 2010; 107(9):1058-70. PMC: 2996922. DOI: 10.1161/CIRCRESAHA.110.223545. View